Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome

Lowell B. Anthony, MD
Published: Friday, Oct 16, 2015



Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

The prospective, randomized, placebo-controlled trial enrolled more than 100 patients, 35 of which participated in exit interviews from the randomized treatment portion of TELESTAR prior to going on the open-label study.

Patients reported symptoms mainly consisting of diarrhea and the frequency of it, physical function, and impact these symptoms had on their quality of life. A total of 33 of the 35 patients participated in interviews, one-third of which were on placebo. Fourtee patients did not report any signs of improvement, 7 patients had somewhat improvement, and 12 had definite improvement. The reduction in diarrhea allowed for better quality of life, Anthony adds.

<<< View more from the 2015 NANETS Symposium



Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

The prospective, randomized, placebo-controlled trial enrolled more than 100 patients, 35 of which participated in exit interviews from the randomized treatment portion of TELESTAR prior to going on the open-label study.

Patients reported symptoms mainly consisting of diarrhea and the frequency of it, physical function, and impact these symptoms had on their quality of life. A total of 33 of the 35 patients participated in interviews, one-third of which were on placebo. Fourtee patients did not report any signs of improvement, 7 patients had somewhat improvement, and 12 had definite improvement. The reduction in diarrhea allowed for better quality of life, Anthony adds.

<<< View more from the 2015 NANETS Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x